Fibrocell Science (FCSC) Misses Q2 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
August 9, 2017 8:01 AM EDTEXTON, Pa., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.
During the second quarter of 2017, we achieved important milestones that continue to advance the development of our gene therapy candidates for the treatment of rare and devastating diseases of the skin and connective tissue with... More
